FUSION regimen: ranibizumab in treatment-naïve patients with exudative age-related macular degeneration and relatively good baseline visual acuity
作者： Jordi Monés , Marc Biarnés , Fabio Trindade , Ricardo Casaroli-Marano
DOI: 10.1007/S00417-012-2009-5
关键词: Regimen 、 Macular degeneration 、 Fluorescein angiography 、 Pro re nata 、 Prospective cohort study 、 Visual acuity 、 Ophthalmology 、 Medicine 、 Ranibizumab 、 Surgery 、 Exudative age-related macular degeneration
摘要: Background To investigate the safety and efficacy of a combined fixed-interval pro re nata regimen ranibizumab (FUSION regimen) for treatment exudative age-related macular degeneration in patients with good visual acuity at baseline. To establish whether similar to monthly regimens can be achieved fewer injections, even acuity.
springer.com
core.ac.uk
sci-hub.se 参考文章(22)
P. Wong, L. Scott, P.-W. Wang, M. Singer, HORIZON Extension Trial of Ranibizumab (LUCENTIS®) for Neovascular Age-Related Macular Degeneration (AMD): Two-Year Safety and Efficacy Results Investigative Ophthalmology & Visual Science. ,vol. 50, pp. 3093- 3093 ,(2009)
Daniel F Martin, Maureen G Maguire, GSet al Ying, Juan E Grunwald, Stuart L Fine, Glenn J Jaffe, None, Ranibizumab and bevacizumab for neovascular age-related macular degeneration. The New England Journal of Medicine. ,vol. 364, pp. 1897- 1908 ,(2011) , 10.1056/NEJMOA1102673
Salomon Y. Cohen, Lise Dubois, Ramin Tadayoni, Franck Fajnkuchen, Sylvia Nghiem-Buffet, Corinne Delahaye-Mazza, Brigitte Guiberteau, Gabriel Quentel, Results of One-Year's Treatment with Ranibizumab for Exudative Age-related Macular Degeneration in a Clinical Setting American Journal of Ophthalmology. ,vol. 148, pp. 409- 413 ,(2009) , 10.1016/J.AJO.2009.04.001
Hassiba Oubraham, Salomon Y Cohen, Sepideh Samimi, David Marotte, Ines Bouzaher, Pierre Bonicel, Franck Fajnkuchen, Ramin Tadayoni, Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration. Retina-the Journal of Retinal and Vitreous Diseases. ,vol. 31, pp. 26- 30 ,(2011) , 10.1097/IAE.0B013E3181DE5609
Philip J. Rosenfeld, Howard Shapiro, Lisa Tuomi, Mary Webster, Julee Elledge, Barbara Blodi, Characteristics of Patients Losing Vision after 2 Years of Monthly Dosing in the Phase III Ranibizumab Clinical Trials Ophthalmology. ,vol. 118, pp. 523- 530 ,(2011) , 10.1016/J.OPHTHA.2010.07.011
Richard F. Spaide, The As-Needed Treatment Strategy for Choroidal Neovascularization: A Feedback-Based Treatment System American Journal of Ophthalmology. ,vol. 148, pp. 1- 3 ,(2009) , 10.1016/J.AJO.2009.04.010
P Mitchell, J-F Korobelnik, P Lanzetta, F G Holz, C Prunte, U Schmidt-Erfurth, Y Tano, S Wolf, Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials British Journal of Ophthalmology. ,vol. 94, pp. 2- 13 ,(2010) , 10.1136/BJO.2009.159160
Anne E. Fung, Geeta A. Lalwani, Philip J. Rosenfeld, Sander R. Dubovy, Stephan Michels, William J. Feuer, Carmen A. Puliafito, Janet L. Davis, Harry W. Flynn, Maria Esquiabro, An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. American Journal of Ophthalmology. ,vol. 143, pp. 566- 583 ,(2007) , 10.1016/J.AJO.2007.01.028
Omesh P. Gupta, Gary Shienbaum, Avni H. Patel, Christopher Fecarotta, Richard S. Kaiser, Carl D. Regillo, A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology. ,vol. 117, pp. 2134- 2140 ,(2010) , 10.1016/J.OPHTHA.2010.02.032
Marc Biarnés, Jordi Monés, Joan R. Villalbi, Lluís Arias, As-needed treatment with ranibizumab 0.5 mg in patients with neovascular age-related macular degeneration European Journal of Ophthalmology. ,vol. 21, pp. 282- 289 ,(2011) , 10.5301/EJO.2010.5766